https://www.selleckchem.com/products/4-hydroxynonenal.html To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery. Studies comparing LMWH and aspirin were retrieved in multiple databases. Review Manager 5.0 was adopted for meta-analysis, sensitivity analysis and bias analysis. Finally, 4460 patients in 6 studies were included, and the eligibility criteria were finally met. The meta-analysis suggested that there was significant difference between LMWH and aspirin groups in DVT (RR = 0.58, 95%CI [0.39, 0.88], P = 0.01; P for heterogeneity = 0.45, I2 = 0%). Postoperative bleeding between the two groups showed no difference (RR = 2.20, 95%CI [0.48, 10.09], P = 0.31; P for heterogeneity = 0.79, I2 = 0%) This study shows that LMWH is a more effective therapy than aspirin for patients with DVT after orthopaedic surgery.Current literature on the safety and efficacy of direct oral anticoagulants (DOACs) in patients of extreme weights are limited, however, they are still being prescribed in these populations. The objective of this study is to describe the safety and efficacy of DOAC therapy in patients of extreme weights for the treatment of venous thromboembolism (VTE) using body mass index (BMI) groups. A multi-site, retrospective cohort design at four hospitals was performed. Patients who experienced an initial VTE between November 2012 and August 2017 and placed on a DOAC were included. Patients were defined as extremely obese (EO) if BMI ≥ 40 kg/m2, obese if BMI 30-39.9 kg/m2, normal/overweight if BMI 18.5-29.9 kg/m2, and underweight if BMI  less then  18.5 kg/m2. The primary efficacy outcome of recurrent VTE and primary safety outcome of major bleeding (MB) within 12 months were compared between weights. Univariate statistical tests and multivariate logistic regression analyses were performed. Rates of recurrent VTE showed no significant differences (p = 0.58)